相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenstr?m Macroglobulinemia
Barbara Muz et al.
CANCER BIOLOGY & THERAPY (2020)
Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy
Micah John Luderer et al.
PHARMACEUTICAL RESEARCH (2019)
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma
Pilar de la Puente et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma
Pilar de la Puente et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
The next generation of novel therapies for the management of relapsed multiple myeloma
Wilson I. Gonsalves et al.
FUTURE ONCOLOGY (2017)
Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome
Shiran Ferber et al.
ELIFE (2017)
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy
W. I. Gonsalves et al.
BONE MARROW TRANSPLANTATION (2016)
P-selectin is a nanotherapeutic delivery target in the tumor microenvironment
Yosi Shamay et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma
Filar de la Puente et al.
BIOMATERIALS (2015)
Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
Barbara Muz et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Jennifer L. Thompson
ANNALS OF PHARMACOTHERAPY (2013)
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
Abdel Kareem Azab et al.
BLOOD (2012)
Bone Marrow Microenvironment in Multiple Myeloma Progression
S. Manier et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632
Marike Marjolijn van Beuge et al.
PHARMACEUTICAL RESEARCH (2011)
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition
Daisuke Tamura et al.
CANCER SCIENCE (2010)
Translating cancer research into targeted therapeutics
J. S. de Bono et al.
NATURE (2010)
Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Douglas A. Stewart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma
Abdel Kareem Azab et al.
BLOOD (2009)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
AM Roccaro et al.
CANCER RESEARCH (2006)
Development of the proteasome inhihitor Veleade((TM)) (Bortezomib)
J Adams et al.
CANCER INVESTIGATION (2004)
分享论文
